Text

The skin can produce its own immune response to control the microbiota

The skin can independently generate immune responses to control the microbiota and prevent infections, without relying on other immune centers.

Innovative Potential of Lonza’s Capsugel® Enprotect® Capsules in Targeted Live Biotherapeutics and Pharmaceutical Applications

Lonza's capsules ensures targeted intestinal delivery enhancing stability and therapeutic efficacy for LBPs and pharmaceutical applications.

Unlocking the hidden world of the small intestine: a new frontier in microbiome science

Cmbio announces a strategic partnership with Nimble Science to deliver first in class high-quality, multi-omic data insights from the small intestine.

Early-life microbiota might influence the severity of respiratory infections

The findings suggest that the microbial communities inhabiting an infant’s nose and throat can play a role in the severity of RSV infections.

Ketogenic diet may help treat autoimmune diseases by altering gut bacteria

The findings suggest that bHB could be a therapeutic alternative to a ketogenic diet. The results also highlight the protective role of the gut microbiota and its metabolites in autoimmune…

Bacteria and other microbial signatures may predict immunotherapy success

The presence of specific microbes in the gut microbiota can serve as biomarkers for predicting the efficacy of immunotherapy.

“Super-donor” microbiota may restore gut health after fecal microbiota transplantation

By suggesting that the diversity and variety of microbial species play a big role in whether the transplanted microbes can successfully colonize a recipient’s gut, the findings could pave the…

Cmbio® strengthens its digital biology platform with acquisition of Eagle Genomics’ assets

The acquisition will enhance its ability to address the needs of a growing market, empowering researchers and industries worldwide.

Revolutionizing treatment for Acute Graft-versus-Host Disease: MaaT Pharma’s groundbreaking Phase 3 results

The live biotherapeutics market is forecasted to exceed $4 billion by 2030, driven by advancements like MaaT013.

Gut to lung: how a new Akkermansia muciniphila strain is reshaping respiratory health

Its emergence in the respiratory health sector represents a paradigm shift, offering promising avenues for innovation and investment.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top